Stock Events

Stock Events

Atyr Pharma 

€0.4230
295
-€0.04-9.03% Wednesday 06:01

Statistics

Day High
0.423
Day Low
0.423
52W High
5.3
52W Low
0.353
Volume
0
Avg. Volume
39
Mkt Cap
26.97M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q1 2026
Q2 2026
Next
-0.11
-0.1
-0.1
-0.09
Expected EPS
-0.08602
Actual EPS
N/A

Financials

14.75%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
329.54MRevenue
48.61MNet Income

Analyst Ratings

19.67Average Price Target
The highest estimate is 28.08.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 471A.MU. It's not an investment recommendation.
NVIDIA
53
NVDA
Microsoft
33
MSFT
Amazon
30
AMZN
AMD
30
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, focusing on immunology and inflammatory diseases, similar to aTyr Pharma's focus on immune modulation for various diseases.
AMGEN
AMGN
Mkt Cap233.78B
Amgen operates in the same biotech space, developing therapies for serious illnesses, including those related to immune system disorders, overlapping with aTyr Pharma's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas of unmet medical need, including inflammatory and respiratory diseases, competing with aTyr Pharma's pipeline.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurology, autoimmune and hematologic disorders, but its expansion into novel therapeutic areas and biologics can pose competition to aTyr Pharma's novel biologic therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals targets serious diseases with its drugs, including cystic fibrosis, which involves managing inflammation and immune response, areas aTyr Pharma is also exploring.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie works on advanced therapies in immunology, oncology, and virology, including treatments for inflammatory diseases, directly competing with aTyr Pharma's focus on immune modulation.
Novartis
NVS
Mkt Cap292.35B
Novartis offers a broad range of healthcare products in pharmaceuticals, including treatments for autoimmune diseases and inflammation, making it a competitor in the same therapeutic areas as aTyr Pharma.
Pfizer
PFE
Mkt Cap159.36B
Pfizer's wide range of therapeutic areas, including inflammation and immunology, puts it in direct competition with aTyr Pharma, especially with its focus on innovative treatments for diseases.
Merck
MRK
Mkt Cap366B
Merck operates in various therapeutic areas, including immunology, and its research into novel therapies for immune-mediated diseases competes with aTyr Pharma's focus.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a diverse portfolio in respiratory, cardiovascular, renal, metabolism, and immunology, including therapies for inflammation and autoimmune diseases, competing with aTyr Pharma's research and development focus.

About

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Show more...
CEO
Sanjay S. Shukla
Employees
58
Country
United States
ISIN
US0021202025
WKN
000A2PM86

Listings

MU
DE
471A.MU
STU
DE
471A.STU
STU
DE
471.STU
F
DE
471A.F

0 Comments

Share your thoughts

FAQ

What is Atyr Pharma stock price today?▼
The current price of 471A.MU is €0.42 EUR — it has decreased by -9.03% in the past 24 hours. Watch Atyr Pharma stock price performance more closely on the chart.
What is Atyr Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Atyr Pharma stocks are traded under the ticker 471A.MU.
Is Atyr Pharma stock price growing?▼
471A.MU stock has fallen by -11.13% compared to the previous week, the month change is a -4.94% fall, over the last year Atyr Pharma has showed a -91.19% decrease.
What is Atyr Pharma market cap?▼
Today Atyr Pharma has the market capitalization of 26.97M
When is the next Atyr Pharma earnings date?▼
Atyr Pharma is going to release the next earnings report on November 05, 2026.
What were Atyr Pharma earnings last quarter?▼
471A.MU earnings for the last quarter are -0.1 EUR per share, whereas the estimation was -0.11 EUR resulting in a +9.41% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Atyr Pharma revenue for the last year?▼
Atyr Pharma revenue for the last year amounts to 329.54M EUR.
What is Atyr Pharma net income for the last year?▼
471A.MU net income for the last year is 48.61M EUR.
How many employees does Atyr Pharma have?▼
As of September 04, 2026, the company has 58 employees.
In which sector is Atyr Pharma located?▼
Atyr Pharma operates in the Health & Wellness sector.
When did Atyr Pharma complete a stock split?▼
Atyr Pharma has not had any recent stock splits.
Where is Atyr Pharma headquartered?▼
Atyr Pharma is headquartered in SAN DIEGO, United States.